A team of researchers of the Barcelonaβeta Brain Research Center (BBRC) participated in the 11th Clinical Trials on Alzheimer’s disease (CTAD), which took place in Barcelona, from the 24th to the 27th of October.
The Scientific Director of the Alzheimer’s Prevention Program at BBRC, José Luis Molinuevo, participated in the opening ceremony, several meetings and the symposium ‘Biomarkers in Stage 1, 2 and 3 Disease’ together with Samantha Budd Haeberlein from Biogen in Cambridge, Christopher C. Rowe from the Department of Molecular Imaging of the University of Melbourne, Maria Carrillo from the Alzheimer’s Association, and Clifford R. Jack from the Department of Radiology of the Mayo Clinic in Rochester.
In addition, BBRC presented two posters. On the one hand, Oriol Grau, researcher of the Clinical, Biomarker and Risk Factors research group at BBRC, presented the results of the study ‘Cognitive and brain structural correlates of insomnia symptoms in middle-aged healthy adults’. On the other hand, Gemma Salvadó, predoctoral researcher of the Neuroimaging research group at BBRC, presented a poster on behalf of the AMYPAD project, entitled ‘Supratentorial white matter appears to be a better reference region than standard infratentorial regions for longitudinal quantification of [18F]flutemetamol scans’.
CTAD brought together to Barcelona worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments. José Luis Molinuevo is one of the members of CTAD’s Scientific Committee and the EU/US CTAD Task Force.